- FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF
-
Disclosed herein are flavonoid compounds of formula (I) with variables as defined herein, compositions containing these compounds, methods for their synthesis, and uses of these compounds. In particular, there is provided methods of preventing and or mitigating the damage caused by cell apoptosis or cell necrosis by administration of the flavonoid compounds. Also provided are methods for inhibiting pro-apoptotic signalling kinase activity (such as JNK and p38a) in a subject while regulating and activating extracelluar signal regulated kinase (ERK). Also disclosed are methods of treating a diseases associated with the presence of reactive oxidative species (ROS), particularly wherein the subject is suffering ischemia or repefusion injury, by administration of the flavonoid compounds.
- -
-
Paragraph 0164; 0165
(2013/03/26)
-
- O-Aminophenol derivatives and colorants containing these compounds
-
The object of the present invention is novel o-aminophenol derivatives of Formula (I), or physiologically compatible water-soluble salts thereof, as well as an agent for the coloring of keratin fibers, especially of hair, which contains at least one o-ami
- -
-
-
- O-AMINOPHENOL DERIVATIVES AND DYES CONTAINING THESE COMPOUNDS
-
The invention relates to novel o-aminophenol derivatives of formula (I) or to their physiologically compatible water-soluble salts, and to an agent for dying keratin fibers, particularly hair, which contains at least one o-aminophenol derivative of formula (I).
- -
-
Page/Page column 17-18
(2010/10/20)
-
- Novel compounds for hair coloring compositions
-
Hair-coloring compositions comprise at least one self-coupling compound of Formula (1) wherein R is a moiety selected from H, C1-3 alkyl and C1-3 hydroxyalkyl; R1 is a C1-3 alkylene radical and R2 is
- -
-
-
- 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS
-
Compounds of the formula (I) provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula (I) inhibit PTP-1 B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity.
- -
-
Page/Page column 96
(2010/02/07)
-
- Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
-
Described are cyclohexylamine derivatives of Formula I Formula VI andFormula VIa and pharmaceutically acceptable salts thereof, wherein R1, g, *, R, V, B, E, Y, G, H, X1, and d are as defined in the description. The compounds of Formulas I and VI are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, trauma, hypoglycemia, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence.
- -
-
-
- Synthesis of high-specific-radioactivity 4- and 6-[18F]fluorometaraminol- PET tracers for the adrenergic nervous system of the heart
-
Fluorine-18 (t12:109.8min)-labeled analogues of metaraminol, 4-[18F]FMR ((1R,2S)-2-amino-1-(4-[18F]fluoro-3-hydroxy phenyl)-1-propanol) and 6-[18F]FMR ((1R,2S)-2-amino-1-(2-[18F]fluoro-5-hydroxyphenyl)-1-propanol), were synthesized as new positron-emission-tomography (PET) tracers for mapping cardiac adrenergic nerve terminals. Copyright
- Langer, Oliver,Dollé, Frédéric,Valette, Héric,Halldin, Christer,Vaufrey, Fran?oise,Fuseau, Chantal,Coulon, Christine,Ottaviani, Michéle,N?gren, Kjell,Bottlaender, Michel,Maziére, Bernard,Crouzel, Christian
-
p. 677 - 694
(2007/10/03)
-